Ointment for septic and open wounds
SUBSTANCE: ointment contains wax 13-15 wt %, glycerol 15-20 % and vegetable oil; the prepared ointment mass is exposed to ozone for 15-20 min in a yield amount of 10 mg/l.
EFFECT: invention provides the advanced healing efficacy with no side effects by reducing the time of wound cleansing from purulo-necrotic tissues.
The invention relates to medicine, namely to compositions of ingredients that have medicinal purpose by external use on the human body.
Closest to the claimed ointment is an ointment for treatment for frostbite (patent RF №2478368, IPC AC 9/06, AK 36/21, AK 9/42, A01P 17/26, 2013), including wax, amaranth oil, glycerin, with the following ratio of components, mass. %: wax 13-15, glycerin 15-20, amaranth oil the rest.
This ointment is more versatile than existing in the field of its application for different types of wounds, but the main drawback is the slow cleanse wounds from pus, which delays healing effect.
The technical result of the invention is aimed at increasing the effectiveness of healing action in the absence of side effects due to the shortening of cleansing the wound of necrotic tissue.
The technical result is achieved in that ointment, including the bee product contains as bee wax product, as fat product of plant oil, as a means of activating the metabolism, glycerol, ozone in the following ratio of components, mass. %: wax 13-15; glycerin 15-20; vegetable oil the rest, with the resulting mass ointment ozonize for 15-20 min, and the ozone on you�ode is 10 mg/L.
Comparative analysis with the prototype showed that the claimed composition of the ointment differs from the known fact that the mass of ointment ozonize for 15-20 min, and the ozone output is 10 mg/L.
Ointment is manufactured as follows.
Vegetable oil heated to boiling in a steam bath, after which it added to the wax to dissolve. The resulting mass is stirred and left to simmer 5 minutes, then remove from fire, cool to room temperature, add the glycerin, mix thoroughly and the resulting mass ointment ozonize for 15-20 min, and the ozone output is 10 mg/L.
The cooled ointment is applied sterile medical spatula in a thin layer on a sterile cloth and applied on the wound surface.
The validity of the ointment more than 2 years from the date of preparation when stored in a cool dark place.
therapeutic properties of ointments are as follows.
Vegetable oil contains triglycerides and polyunsaturated fatty acids that promote tissue regeneration.
The wax used for other ointments bee products has the lowest reactivity, in the presence of triglycerides is able to allocate the wound oxidized oxygen, contributing to tissue regeneration.
Glycerin has a softening and simultaneously.�but astringent action, has a high hygroscopic and lubricating properties. When applied to the wound surface it activates metabolic processes and has hemostatic effect.
Ozone when applied topically in the form of ozonized solutions or oil, etc. has a direct oxidative effect on the membrane of microorganisms. Ozone kills virtually all types of bacteria, fungi, viruses and protozoa. While gram-positive bacteria and capsular viruses having lipid bilayer, are particularly sensitive to oxidation, in addition, ozone causes bactericidal effect, which is mediated by nonspecific activation of the protection system (activation of phagocytosis, enhanced synthesis of cytokines-interferons, tumor-necrotizing factor, interleukins, as well as components of cellular and humoral immunity). In addition, ozone restores metabolic reactions in the tissues at the site of inflammation
In addition, ozone restores metabolic reactions in the tissues at the site of inflammation and corrects the pH of the oxidation of double bonds.
The analgesic effect of ozone is due, on the one hand, the oxidation decomposition products of protein molecules, the so-called alopaticos acting on the nerve endings in the damaged tissue and determining the intensity of the pain response, on the other hand, normalizes�antioxidant system and thus reducing the amount of toxic molecular products of lipid peroxidation in cell membranes, which alter the function membranotropic of enzymes involved in the synthesis of adenosine triphosphate (ATP), the maintenance of tissues and organs, promotes epithelialization and healing.
Ointment plastic and due to the content based on voska-melanopterus mixture has a high penetration in biological tissue.
Ointment is completely harmless and has no side complications.
therapeutic effect of the ointment was tested in the whole range of changes in the quantitative content of the components.
The ointment was tested on twenty-five patients with various types of burn wounds, bedsores, trophic ulcers, open and festering wounds and chilblains.
Patient A., 20 years old, Diagnosis: burn 2-3 degrees in the area of the face, neck, chest, anterior surface. After 10 days of treatment with an ointment, the patient remained soft skin, slightly flushed.
Patient Z., 76 years old, suffering from trophic ulcers of both legs for 15 years. Was treated repeatedly in the hospital and clinics to no avail. After applying the ointment ulcers healed within 1.5 months with tender scar tissue.
Patient B., 56 years old, came with a bitten wound (dog bite) a month after unsuccessful treatment in a clinic. After applying the ointment, the wound healed � for 2 weeks.
Application of the ointment when frostbite gave a positive result. Very quickly starred swelling, were observed intoxication, ligation went smoothly, as the dressings do not stick to the wound surface and freely removed.
Ointment contains cheap, widely available ingredients, the composition is stable, easy to manufacture. Its healing properties can be recommended in clinical therapy in combat.
Ointment to treat sores and open wounds, including wax, glycerin, vegetable oil in the following ratio of components, mass. %: wax 13-15; glycerin 15-20; vegetable oil the rest, characterized in that the mass of ointment ozonize for 15-20 min, and the ozone output is 10 mg/L.
SUBSTANCE: invention relates to medicine, namely to combustiology, and can be applied in process of treating burn wounds of III a and III b degree. For this purpose applied are cultured dermal allofibroblasts on 5-8 passage with concentration 250000 cells/ml as part of composition, which includes as carrier hydroxyethylcellulose natrosol and native collagen. After uniform distribution of medication on wound surface relief fixing with inert mesh covering "Lomatul-N" is carried out.
EFFECT: invention makes it possible to achieve fast recovery skin, reduction of probability of burn disease complications, improvement of functional and cosmetic results of treatment.
1 dwg, 2 ex
SUBSTANCE: burn-treating composition for local application based on Vaseline lanolin, or carbopol, or hydrogel; as an active substance, the composition contains 5% dry extract of the herbal raw material big-flowered self and self-heal containing 60% rosmarinic acid.
EFFECT: above composition is effective for treating burns; it is non-toxic.
7 tbl, 10 ex, 12 dwg
SUBSTANCE: invention refers to medicine, namely to physiotherapy, dermatology and cosmetology, and can be used in stimulating regenerative processes in the face and/or neck skin. That is ensured by performing three stages, first two of which involve preparing to the third one. The first stage involves blood sampling from the patient, recovering the blood plasma, and enriching it with thrombocytes; the purified and enriched plasma is administered intradermally under the skin. Two days later, the second stage follows that involves the subcutaneous injections of hyaluronic acid. The third stage is performed 2-3 days later to expose different skin layers to laser light passing through different face and/or neck sections two to five times for one procedure. Passing once involves the alternating short-wave and long-wave laser exposure at a wave length of 1564-2940 nm. The procedure is repeated every 3-5 days with an increasing laser beam pulse energy from 35 mJ to 65 mJ.
EFFECT: method provides the safe effective stimulation of the regenerative processes in the face and/or neck skin ensured by the complex exposure covering different layers of derma and epidermis and involving different regeneration links.
SUBSTANCE: invention represents an agent for treating septic wounds, pus pockets and trophic ulcers containing betaine hydrochloride, methyluracil, trimecaine, pepsin powder and polyethylene oxide 400 with the ingredients taken in certain proportions, wt %, and polyethylene oxide 400 is taken in an amount of 87.0-84.0 ml.
EFFECT: invention provides fastening necrolysis, intensifies bactericidal action, stimulates regeneration, prevents secondary infection.
SUBSTANCE: group of inventions refers to medicine, namely to dermatology and surgery, and can be used for skin regeneration, repair and grafting. That is ensured by using an absorbable multilayer structure. That is preceded by preparing (adapting) this structure by exposing to an UV lamp at an emitting power of 10-20 W at 15-45 cm from a collagen sponge surface of the membrane for 2-4 hours. Alternatively, the adaptation procedure is developed by cross-linking with dehydration and thermal treatment in the vacuum medium at a pressure <200 mbar and 100°C for 24 hours or with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in a water solution containing approximately 0.1-0.6 g of EDC in approximately 0.3-2 g of the collagen sponge matrix. Cross-linking agents, such as hyaluronan, hexethylene diisocyamate, N-hydroxysuccinimide (NHS) or hyoxal are used. The above absorbable multilayer structure comprises a barrier laminate of a purified collagen made of a natural collagen-containing material. The barrier laminate contains a barrier layer comprising a smooth barrier surface and a fibrous surface on the side opposite the above smooth surface. Additionally, the matrix layer comprises the collagen sponge material made of pig skin. The presented multilayer structure is adapted so that the matrix layer is absorbed by the body within approximately 2-5 weeks, while the collagen barrier laminate is absorbed substantially completely within approximately 6-11 weeks.
EFFECT: group of inventions provides the effective skin replacement for the purpose of skin reconstruction, repair and regeneration, eg following surgical interventions.
35 cl, 3 dwg, 5 ex
SUBSTANCE: invention represents an agent for accelerating wound healing and tissue regeneration, containing oxymethyluracil, loratadine, sodium alginate, glycerol, a stabilising agent, a preserving agent and distilled water; the ingredients of the agent are taken in certain proportions, wt %.
EFFECT: accelerating wound healing and tissue regeneration, as well as possesses the pronounced immunomodulatory, anti-inflammatory, anti-allergic, anti-pruritic, anti-edematous and wound-healing action.
2 cl, 3 ex, 1 tbl
SUBSTANCE: invention relates to chemistry and presents a conjugation product, comprising polysaccharides T1 and T2, where the monosaccharides which form the polysaccharides T1 and T2 are bonded to each other by alpha-1,4-glycosidic links. At least one of the polysaccharides T1 and/or T2 comprises at least one amino group. T1 and T2 are bonded to each other covalently by a linker. T1 and/or T2 carry m groups -(L-A), wherein A is glucosaminoglycan or a derivative of glucosaminoglycan, glucosaminoglycan or a derivative of glucosaminoglycan with fluorescence labels, L is a second linker, by which T1 and/or T2 are covalently bonded to A, and m is at least 1.
EFFECT: invention also relates to a pharmaceutical composition, comprising a bonded product; use of the product in medicine and cosmetology and to the method of preparation of the bonded product.
22 cl, 5 ex
SUBSTANCE: invention represents an anti-inflammatory antibacterial wound-healing agent containing a polyethylene oxide base with molecular weight 400 (PEO-400) as a forming agent, as well as polyethylene oxide with molecular weight 1,500 (PEO-1500); an active substance is chloramphenicol and methyluracil; the agent is characterised by the fact that it additionally contains rifampicin and/or cycloserine; the cycloserine content in the rifampicin mixture is specified within the range of 18 to 82 wt %, whereas the ingredients are taken in certain ratio, wt %.
EFFECT: invention provides more effective healing of open wounds, ulcers, bedsores, as well as increased necrolytic effect, reduced exudation, and also a lower risk of allergic reactions.
3 cl, 9 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and concerns a method for making an activated leukocyte composition involving human leukocyte incubation, exposure to hypotonic shock and addition of physiologically acceptable saline in an amount sufficient for the reconstitution of isotonicity, to the leukocytes. The group of inventions also concerns using: the activated leukocyte composition in preparing a drug for wound healing; a wound healing dressing containing the above composition.
EFFECT: group of inventions provides preparing the composition containing a 90 times increase of the leukocyte count as compared to the known state-of-the-art methods.
16 cl, 3 dwg, 6 tbl, 3 ex
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for the treatment of local skin I-II degree radioreactions on irradiation fields after neutron therapy in patients with head and neck malignancies. For this purpose the applications of ozonised sunflower oil with peroxide number 18% and acid number 71 mg KON/g are performed on the area of the affected skin. The impact is performed after a session of neutron therapy 1-2 times per day for 4-5 days.
EFFECT: method ensures the reduction of the number of radioreactions and skin injuries due to optimally selected parameters of the applied medication, capable of the fast arrest of pain syndrome, reduction of oedema of surrounding tissues, wound-healing action in specific irradiation conditions.
4 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry and represents a pharmaceutical composition for the external application for the treatment of skin diseases in the form of a cream, which includes as an active substance methylprednisolone aceponate in a therapeutically effective amount and a lipophilic base, characterised by the fact that as the lipophilic base it contains petrolatum, liquid paraffin and oil of castor oil plant seeds and additionally white bee wax, with the components of the composition being in a specified ratio in g/100 g of the composition.
EFFECT: invention provides the creation of the stable composition, improved pharmacological properties and absence of an irritating effect.
SUBSTANCE: group of inventions refers to a pharmaceutical composition in the form of a soft dosage form for treating locomotor disorders, possessing anti-inflammatory, anaesthetic and anti-oedematous action, containing a combination of heparin sodium salt, dexpanthenol, diethylene glycol monoethyl ether and/or dimethylsulphoxide and target additives. The latter are presented by a gelation agent, a solvent/a solubiliser, a neutraliser, a flavouring agent/a moistening agent and water. The invention also discloses a method for producing the pharmaceutical composition.
EFFECT: reducing side actions, particularly allergic responses; it is characterised by high pharmacological activity, and simplified method for producing.
15 cl, 5 ex, 3 tbl
SUBSTANCE: pharmaceutical composition possessing a therapeutic action on various skin pathologies contains triptantrin, chitosan and distilled water, a lanoline and Vaseline mixture and protein-nucleic hydrolyzate of the salmonid fishes milt in a certain mixture ratio.
EFFECT: composition enables increasing the clinical effectiveness in the skin pathologies of various origins and extending the range of pharmaceutical compositions having the therapeutic effect on the various skin pathologies.
3 tbl, 4 dwg, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry, namely to production of medications for treating dermatosis. Medication according to invention, made in form of cream, contains mometasone furoate, preservative, hydrophilic no-aqueous solvent, emulsifying agent of 1st kind, emulsifying agent of 2nd kind, emollient, disodium edetate (trilon B), pH-regulating agent, and purified water in quantities, given in invention formula.
EFFECT: invention can be applied for treating inflammatory diseases and itching in case of dermatosis, yielding to glycocorticosteroid therapy.
9 cl, 3 tbl, 3 ex
SUBSTANCE: pharmaceutical composition contains drug substances and a consistency-forming base. According to the invention, it contains anaesthetics as drug substances specified in a group: anaesthesine, lidocaine, promedol and antiseptic specified in a group of: ethacridine lactate, Furacilin, dioxidine, chlorhexidine, boric acid, 0.5% silver solution in the following ratio, g in 1 ml of the mixture: anaesthetics 0.00001-0.5; antiseptics 0.00001-0.5; consistency-forming base - the rest. Besides, it contains lysozyme in an amount of 0.1-0.3 g per 1 ml of the mixture, alpha-lipoic acid as an antioxidant in an amount of 0.00001-0.5 g per 1 ml of the mixture, regenerants specified in a group of: pantothenic acid, calcium pantotenate, beta-carotene, coenzyme Q, sodium deoxyribonucleate, inosine, vitamins A, D, E, K in an amount of 0.00001-0.5 g per 1 ml of the mixture, anabolics specified in a group of: methyluracil, riboxinum, potassium orotate, orotic acid, L-carnitine in an amount of 0.00001-0.5 g per 1 ml of the mixture, glycyrrhizic acid and/or its salts in an amount of 0.00001-0.5 g per 1 ml of the mixture, recombinant interferon specified in a group of: recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma in an amount of 100-1,000,000 International units, glucocorticoids specified in a group of: hydrocortisone, prenisolone, polcortolone in an amount of 0.00001-0.5 g per 1 ml of the mixture. The consistency-forming base contains the components specified in a group: hypromellose, sodium alginate, acetyl phthalyl cellulose, macrogol, polyvinylpyrrolidone.
EFFECT: improving the properties of the composition.
9 cl, 11 ex
SUBSTANCE: what is described is a bioactive wound coating of a hydrogel nanocomposite, which contains antimicrobial and antioxidant ingredients: silver-modified montmorillonite and fullerenol used to optimise the clinical course of the wound process, to prevent and suppress a wound infection. The wound coating can be used to treat gun-shot injuries, severe mechanical injuries, infected and uninfected wounds, including septic and persistent, granulating wounds following deep thermal, chemical and radioactive burns, in the combined therapy of trophic ulcers and bed sores at hospital, in the outpatient setting and in the field. The wound coating is elastic, not fragmented in dressing that facilitates wound care. A high sorption ability of the wound coating matrix, including of coarse-molecular ingredients of the wound effluent, provides the fast elimination of the wound bed. Using the hydrogel, i.e. possessing high degree of hydration, the wound coating meets the modern wound management in the humid medium.
EFFECT: optimum conditions for the early activation of the repair processes.
5 dwg, 2 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compositions for local application for the prevention and treatment of local eye pathologies, in particular inflammatory keratites and conjunctivitis and the dry eye syndrome, which contain as active ingredients polyunsaturated fatty acids of the omega-3 and omega-6 type, namely, EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with vitamin E acetate and combined into a stable composition in a hydrogel, that is in the disperse form in a water solution, containing one or more gel-forming polymers. The claimed compositions are especially recommended for application as artificial tears.
EFFECT: invention provides an increased efficiency of the prevention and treatment of eye pathologies.
15 cl, 15 tbl, 3 dwg, 7 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, more specifically to a composition for treating dermatologic diseases, preferentially skin itching. The composition causes antiallergic action and is used in treating allergic reactions (rash, urticaria), insect bites, ultraviolet erythema and skin burns. The pharmaceutical composition contains azelastine hydrochloride and benzocaine as active substances, and a hydrophobic ingredient, a hydrophilic ingredient, an emulsifying agent and a pH corrective agent as additive agents. As the pH corrective agent, the composition contains preferentially succinic acid. The pharmaceutical composition is presented as a soft dosage form, preferentially in the form of a cream.
EFFECT: composition according to the invention is characterised by high pharmacologic activity, good package extrusion, and storage-stability.
9 cl, 1 tbl, 14 ex
SUBSTANCE: therapeutic agent contains carboxymethyl cellulose sodium salt as a base and a combination of antiseptic, 0.01% Myramistinum and metronidazole as therapeutic ingredients. The invention provides preparing the therapeutic agent possessing the antiseptic, wound-healing and sorption action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynaecology, otorhinolaryngology.
EFFECT: agent possesses the higher efficacy.
2 tbl, 2 ex
SUBSTANCE: therapeutic agent contains an alloy of polyethylene oxide of molecular weight 400 and 1500 as a base and comprises a combination of antiseptic, benzalkonium chloride and metronidazole as therapeutic ingredients. The invention provides preparing the therapeutic agent possessing the antimicrobial, sorption and wound-healing action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynaecology, otorhinolaryngology.
EFFECT: agent possesses the higher efficacy.
2 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a composition for treating asthenic syndrome in patients with dyscirculatory encephalopathy. An ester-oil composition for treating asthenic syndrome in the patients with dyscirculatory encephalopathy contains eucalyptus, mint, pine, cedar, lavender, carnation, flax essences taken in certain relations.
EFFECT: composition is effective for treating asthenic syndrome in the patients with dyscirculatory encephalopathy; it causes the selective harmonising action on the central nervous system, regulates the emotional status, improves cognitive functions, reduces clinical manifestations of asthenic syndrome considerably and improves the quality of life in the patients with dyscirculatory encephalopathy.
1 tbl, 1 ex